{
  "report_rows": [
    {
      "kpi": "Q2 adjusted diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$5.35 vs. cons $5.29",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$2.11B vs. cons $2.10B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 organic revenue growth",
      "prediction": "IN-LINE",
      "answer": "pred ~4.5% vs. cons 4.5%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adjusted diluted EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$22.10 vs. cons $21.91 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic revenue growth guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~5.5% vs. cons 5.5% (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "Adjusted diluted EPS guidance",
      "prediction": "LOWER",
      "answer": "guide ~$5.58 vs. cons $5.65 (Q3 2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 2.4,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.2,
  "day5_path": "STABILIZE",
  "day5_rationale": "A modest Q2 beat and FY2026 EPS midpoint near $22.10 versus $21.91 consensus support the initial move, but Q3 guidance near $5.58 versus $5.65 consensus shifts earnings into Q4 rather than materially lifting out-period estimates, limiting follow-through.",
  "day5_confidence": "MEDIUM"
}